Alexandria Real Estate Equities, Inc. Earnings Recaps
Q1 2026
Apr 29, 2026
Headline Summary: Shares of Alexandria Real Estate Equities fell 9.9% after Q1, as investors reacted to a soft leasing quarter and signs of continued leasing headwinds, notably the absence of any public biotech leases—the first time in company history. Management struck a cautious tone on the near-term operating environment and reiterated a focus on balance sheet strength and dispositions. Key Takeaways:
Key takeaways
- Leasing activity was notably weak, with management disclosing this was "one of our lower quarters" and, unprecedentedly, that no public biotech leases were signed in Q1.
- The company remains on track with its core/non-core asset disposition plan, highlighting a high-watermark sale in San Francisco at $1,645 per sq. ft., albeit on an only 40% occupied asset.
- Management emphasized progress on reducing capital expenditure and continued efforts to maintain a strong, flexible balance sheet.
- The transaction market for life science assets is described as improving, but realization of targeted dispositions remains key for the 2026 reset.
- 78% of ARR is derived from mega campuses and 80% of the top 20 tenants are investment grade or large-cap, supporting balance sheet resilience in a challenging operating backdrop.
Q3 2025
Oct 29, 2025
Alexandria Real Estate Equities reported challenges in Q3 2025, with declines in FFO per share and occupancy, but remains strategically positioned for recovery in the life science sector and maintains a strong balance sheet.
Key takeaways
- FFO per share declined, coupled with a decrease in occupancy, signaling a need for continued vigilance in asset management.
- Alexandria's balance sheet is one of the strongest among REITs, with an average remaining debt maturity of 11.6 years and over $4 billion in liquidity.
- The company aims to reduce non-income-producing assets from 20% to 10-15% of gross assets, drawing on lessons from past market disruptions.
- Early signs of recovery in the biotech market are emerging, amidst ongoing regulatory challenges faced by the FDA due to the government shutdown.
- Alexandria emphasizes its unique position in the life science real estate market, navigating current headwinds with resilience and strategic foresight.